Eflornithine + Lomustine Extends Survival in IDH-Mutated Astrocytoma: STELLAR Study Results

18 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Discover how the combination of eflornithine and lomustine significantly improves overall survival (OS) and progression-free survival (PFS) in patients with recurrent WHO grade 3 IDH-mutated astrocytoma. This video breaks down the key findings from the phase 3 STELLAR study (NCT02796261), presented at the 2025 Society of Neuro-Oncology Annual Meeting. Learn about the study design, patient outcomes, safety profile, and why this treatment approach marks a significant advancement in neuro-oncology. Ideal for healthcare professionals, researchers, and patients seeking the latest in brain cancer treatment innovations.
Key Topics Covered:
- STELLAR study design and patient population
- OS and PFS benefits of eflornithine + lomustine vs. lomustine alone
- Safety profile and toxicity management
- Implications for IDH-mutated astrocytoma treatment
NeuroOncology #BrainCancer #STELLARStudy #IDHMutatedAstrocytoma #Eflornithine #Lomustine #ClinicalTrials #CancerResearch #OncologyNews
Categoria
Oncology
Commenta per primo questo video.

Prossimo